Zoetis said Dr. Linda Rhodes retired from the Board of Directors on May 21, 2024, before the 2024 Annual Meeting of Shareholders, in accordance with the company's director retirement policy.

1. 01

   Zoetis said Dr. Linda Rhodes retired from the Board of Directors on May 21, 2024, before the 2024 Annual Meeting of Shareholders, in accordance with the company's director retirement policy.

2. 02

   The company said shareholders approved an Officer Exculpation Amendment at the May 22, 2024 annual meeting that exculpates certain officers to the extent permitted by the Delaware General Corporation Law. It said the amendment took effect the same day upon the filing of the Restated Certificate of Incorporation.

3. 03

   Zoetis said all 12 sitting directors were elected at the annual meeting to serve one-year terms until the 2025 Annual Meeting of Shareholders. It added that the non-binding advisory vote on the executive compensation program was approved, with 351,133,259 votes for and 34,984,587 against.

4. 04

   The company said a shareholder proposal on the director resignation policy was not approved, with 53,787,299 votes for and 331,848,848 against. Zoetis also said the proposal to ratify KPMG LLP as independent auditor for the fiscal year ending December 31, 2024 was approved, with 401,445,315 votes for.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.